[Relevance of genetic polymorphisms in voriconazole neurotoxicity: case report in a pediatric patient].
作者信息
Martín-Roldán Alicia, Merino-Pardo Alejandra, Algarra-Sánchez Esther, Vendrell Margarita Cuervas-Mons
机构信息
Servicio de Farmacia, Hospital Universitario Virgen de las Nieves, Granada, España.
Servicio de Farmacia, Hospital Infantil Universitario Niño Jesús, Madrid, España.
出版信息
Rev Esp Quimioter. 2025 Mar 3;38(2):145-147. doi: 10.37201/req/112.2024. Epub 2025 Feb 20.
Abstract
摘要
相似文献
1
[Relevance of genetic polymorphisms in voriconazole neurotoxicity: case report in a pediatric patient].[伏立康唑神经毒性中基因多态性的相关性：一名儿科患者的病例报告]
Rev Esp Quimioter. 2025 Mar 3;38(2):145-147. doi: 10.37201/req/112.2024. Epub 2025 Feb 20.
2
A case-report of unpredictable and massive voriconazole intoxication in a patient with extensive CYP2C19 and CYP2C9 polymorphisms.广泛 CYP2C19 和 CYP2C9 多态性患者出现不可预测和大量伏立康唑中毒的病例报告。
Drug Metab Pharmacokinet. 2013;28(5):439-41. doi: 10.2133/dmpk.dmpk-13-nt-007. Epub 2013 Apr 2.
3
Effect of cytochrome P450 2C19 polymorphisms on the clinical outcomes of voriconazole: a systematic review and meta-analysis.细胞色素P450 2C19基因多态性对伏立康唑临床疗效的影响：一项系统评价和荟萃分析
Eur J Clin Pharmacol. 2016 Oct;72(10):1185-1193. doi: 10.1007/s00228-016-2089-y. Epub 2016 Jul 8.
4
Effect of Therapeutic Drug Monitoring and Cytochrome P450 2C19 Genotyping on Clinical Outcomes of Voriconazole: A Systematic Review.治疗药物监测和细胞色素 P450 2C19 基因分型对伏立康唑临床结局的影响：系统评价。
Ann Pharmacother. 2021 Apr;55(4):509-529. doi: 10.1177/1060028020948174. Epub 2020 Aug 8.
5
Association of , and polymorphisms and voriconazole plasma concentrations in Uygur pediatric patients.维吾尔族儿科患者中 、 和 基因多态性与伏立康唑血药浓度的相关性
Pharmacogenomics. 2023 Feb;24(3):141-151. doi: 10.2217/pgs-2022-0159. Epub 2023 Jan 31.
6
Effects of CYP2C19, CYP2C9 and CYP3A4 gene polymorphisms on plasma voriconazole levels in Chinese pediatric patients.CYP2C19、CYP2C9和CYP3A4基因多态性对中国儿科患者伏立康唑血药浓度的影响。
Pharmacogenet Genomics. 2022 Jun 1;32(4):152-158. doi: 10.1097/FPC.0000000000000464. Epub 2022 Jan 25.
7
Impact of CYP2C19, CYP2C9, CYP3A4, and FMO3 Genetic Polymorphisms and Sex on the Pharmacokinetics of Voriconazole after Single and Multiple Doses in Healthy Chinese Subjects.健康中国受试者中单剂和多剂伏立康唑后 CYP2C19、CYP2C9、CYP3A4 和 FMO3 遗传多态性及性别对其药代动力学的影响。
J Clin Pharmacol. 2024 Aug;64(8):1030-1043. doi: 10.1002/jcph.2440. Epub 2024 Apr 23.
8
Impact of cytochrome P450 2C19 polymorphisms on the clinical efficacy and safety of voriconazole: an update systematic review and meta-analysis.细胞色素 P450 2C19 多态性对伏立康唑临床疗效和安全性的影响：一项更新的系统评价和荟萃分析。
Pharmacogenet Genomics. 2022 Sep 1;32(7):257-267. doi: 10.1097/FPC.0000000000000470. Epub 2022 Jul 21.
9
Modulators of very low voriconazole concentrations in routine therapeutic drug monitoring.常规治疗药物监测中伏立康唑低浓度的调节剂。
Ther Drug Monit. 2011 Feb;33(1):86-93. doi: 10.1097/FTD.0b013e31820530cd.
10
Effects of cytochrome P450 3A4 and non-genetic factors on initial voriconazole serum trough concentrations in hematological patients with different cytochrome P450 2C19 genotypes.细胞色素P450 3A4和非遗传因素对不同细胞色素P450 2C19基因型血液病患者伏立康唑初始血清谷浓度的影响。
Xenobiotica. 2017 Dec;47(12):1121-1129. doi: 10.1080/00498254.2016.1271960. Epub 2017 Jan 3.
本文引用的文献
1
Impact of CYP2C19, CYP2C9, CYP3A4, and FMO3 Genetic Polymorphisms and Sex on the Pharmacokinetics of Voriconazole after Single and Multiple Doses in Healthy Chinese Subjects.健康中国受试者中单剂和多剂伏立康唑后 CYP2C19、CYP2C9、CYP3A4 和 FMO3 遗传多态性及性别对其药代动力学的影响。
J Clin Pharmacol. 2024 Aug;64(8):1030-1043. doi: 10.1002/jcph.2440. Epub 2024 Apr 23.
2
The impact of gene polymorphism and hepatic insufficiency on voriconazole dose adjustment in invasive fungal infection individuals.基因多态性和肝功能不全对侵袭性真菌感染患者伏立康唑剂量调整的影响。
Front Genet. 2023 Aug 24;14:1242711. doi: 10.3389/fgene.2023.1242711. eCollection 2023.
3
Effects of CYP2C19, CYP2C9 and CYP3A4 gene polymorphisms on plasma voriconazole levels in Chinese pediatric patients.CYP2C19、CYP2C9和CYP3A4基因多态性对中国儿科患者伏立康唑血药浓度的影响。
Pharmacogenet Genomics. 2022 Jun 1;32(4):152-158. doi: 10.1097/FPC.0000000000000464. Epub 2022 Jan 25.
4
CYP2C9, CYP2C19, CYP2D6 and CYP3A5 polymorphisms in South-East and East Asian populations: A systematic review.CYP2C9、CYP2C19、CYP2D6 和 CYP3A5 多态性在东南亚和东亚人群中的研究：系统评价。
J Clin Pharm Ther. 2019 Aug;44(4):508-524. doi: 10.1111/jcpt.12835. Epub 2019 Apr 13.
5
The Effect of Genetic Polymorphism on the Inhibition of Azole Antifungal Agents Against CYP2C9-Mediated Metabolism.基因多态性对唑类抗真菌药物抑制CYP2C9介导代谢的影响。
J Pharm Sci. 2016 Mar;105(3):1345-8. doi: 10.1016/j.xphs.2016.01.007. Epub 2016 Feb 9.
6
Invasive aspergillosis in pediatric patients.儿童侵袭性曲霉病。
Curr Med Res Opin. 2010 Jul;26(7):1779-87. doi: 10.1185/03007995.2010.487793.
7
CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole.细胞色素P450 2C19基因分型是导致伏立康唑药代动力学高度可变的主要因素。
J Clin Pharmacol. 2009 Feb;49(2):196-204. doi: 10.1177/0091270008327537. Epub 2008 Nov 25.
8
Safety of voriconazole in a patient with CYP2C9*2/CYP2C9*2 genotype.伏立康唑在CYP2C9*2/CYP2C9*2基因型患者中的安全性。
Antimicrob Agents Chemother. 2006 Sep;50(9):3227-8. doi: 10.1128/AAC.00551-06.
9
Identification of a novel variant CYP2C9 allele in Chinese.中国人中一种新型CYP2C9等位基因变体的鉴定。
Pharmacogenetics. 2004 Jul;14(7):465-9. doi: 10.1097/01.fpc.0000114749.08559.e4.
10
Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.细胞色素P450 2C9基因多态性：体外和人体数据的全面综述
Pharmacogenetics. 2002 Apr;12(3):251-63. doi: 10.1097/00008571-200204000-00010.
Zotero 插件